Venus Remedies is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the Production Linked Incentive (PLI) scheme. As per the scheme, the company will be eligible for incentive for the FY 2022-23 to 2027-28, subject to fulfilment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.

Venus Remedies' consolidated net profit surged 77.7% to Rs 23.15 crore on a 60.7% jump in net sales to Rs 202.56 crore in Q2 FY22 over Q1 FY21.

Venus Remedies is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the world.